Since no clinical trial of first-line CAR-T therapy was available for MM with ECOG PS 4 in China, commercial equecabtagene autoleucel, CAR-T therapy targeting BCMA, was proposed and supported by the patient and her family. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.